{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"TRANQUILITY: IL-6, An Important Mediator of CVD     ","description":" The TRANQUILITY trial was designed to evaluate whether pacibekitug can reduce interleukin-6 (IL-6)-driven inflammation, a key inflammatory pathway increasingly linked to cardiovascular risk. Treatment with pacibekitug demonstrated favorable effects on inflammatory and cardiovascular risk biomarkers, supporting IL-6 inhibition as a potential therapeutic strategy for reducing residual inflammatory risk. These findings further strengthen the  evidence implicating IL-6 as an important mediator of cardiovascular disease.&amp;nbsp;   In this episode, Dipti Itchhaporia MD, MACC and Deepak L. Bhatt, MD, MPH, MBA, FACC discuss TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug (IL-6 ligand mAb) targeting inflammation in CKD with high cardiovascular risk.  ","author_name":"ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research","author_url":"http:\/\/www.acc.org","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/43353574\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/207819279"}